What is chronic myelogenous leukemia?
Chronic myelogenous leukemia (CML) is a cancer of the blood in which too many granulocytes, a type of white blood cell, are produced in the bone marrow.
Normally, bone marrow cells mature into several different types of blood cells. CML affects the young blood cells (called blasts) that develop into a type of white blood cell (called granulocytes). The main function of granulocytes is to fight infection. The blasts, which do not mature and become too numerous, remain in the bone marrow and blood.
Symptoms of chronic myelogenous leukemia can develop over a period of months or years. A specific chromosome rearrangement is found in patients with CML. Part of chromosome #9 breaks off and attaches itself to chromosome #22, so that there is an exchange of genetic material between these two chromosomes. This rearrangement changes the position and functions of certain genes, which results in uncontrolled cell growth. Other chromosome abnormalities can also be present.
CML occurs mainly in adults and is rare in children.
What are the symptoms of chronic myelogenous leukemia?
The following are the most common symptoms of chronic myelogenous leukemia. However, each individual may experience symptoms differently. Symptoms may include:
- anemia
- bleeding
- bruising
- fever
- persistent weakness
- fatigue
- aches in bones and joints
- swollen lymph nodes
The symptoms of chronic myelogenous leukemia may resemble other blood disorders or medical problems. Always consult your physician for a diagnosis.
How is chronic myelogenous leukemia diagnosed?
In addition to a complete medical history and physical examination, diagnostic procedures for chronic myelogenous leukemia may include:
- complete blood count
- bone marrow aspiration and/or biopsy - a procedure that involves taking a small amount of bone marrow fluid (aspiration) and/or solid bone marrow tissue (called a core biopsy), usually from the hip bones, to be examined for the number, size, and maturity of blood cells and/or abnormal cells.
- additional blood tests and other evaluation procedures
Treatment for myelogenous leukemia:
Chronic myelogenous leukemia usually changes to acute leukemia 1-5 years after diagnosis and at the acute stage is very difficult to treat. A new treatment for chronic myelogenous leukemia in the early (chronic) stage (Gleevec) induces complete disease remissions in 95% of patients. Gleevec is given by mouth and tolerated by nearly all patients.
Specific treatment for chronic myelogenous leukemia will be determined by your physician based on:
- your age, overall health, and medical history
- extent of the disease
- your tolerance for specific medications, procedures, or therapies
- expectations for the course of the disease
- your opinion or preference
Treatment may include:
- chemotherapy
- biological therapy - using the body's immune system to fight cancer.
- stem cell transplantation
- splenectomy - surgery to remove the spleen.